Baxter International Inc. closed 24.01% short of its 52-week high of $44.01, which the company reached on March 8th.

Baxter International shares surged Thursday after the medical device maker's fourth-quarter results topped estimates.

Barclays reinstated coverage of Baxter (BAX) with an Overweight rating and $39 price target The firm updated its sales projections to reflect ...

Reports Q4 revenue $2.75B, consensus $2.67B. “Our 2024 performance and related strategic milestones reflect Baxter’s (BAX) growing momentum in ...

Baxter International Inc. ( NYSE: BAX) Q4 2024 Earnings Conference Call February 20, 2025 8:30 AM ET Clare Trachtman - SVP and Chief IRO Brent Shafer - Chairman, and Interim CEO Heather Knight - COO ...

Following the completion of a massive restructuring plan, the medical equipment giant projects 4% to 5% sales growth this ...

Shares of Baxter International on Thursday rose on pace for the largest percent increase since March 2020 after fourth-quarter sales and outlook for the first quarter and 2025 beat Wall Street ...

Q4 2024 Management View Interim CEO Brent Shafer highlighted the completion of the Vantive sale as a significant milestone in Baxter's transformation strategy and noted the company's focus on ...

Baxter International Inc. (NYSE:BAX) is expected to report an EPS of $0.81 and revenue of approximately $2.67 billion for its ...